Beijing, Shanghai, Guangzhou, and Shenzhen Rally to Propel Biomanufacturing with $52.5B Funds, Ambitious Output Targets, and Dedicated Legislation

Recently, VCBeat has observed that Beijing, Shanghai, Guangzhou, and Shenzhen—the four first-tier cities in China—have been taking intensive actions to support the development of the biomanufacturing industry through policies, funding, and other measures.

Shanghai Makes Major Moves in Financial Support, with Shanghai State-Owned Investment Company Continuously Advancing the Construction of Its Fund Matrix,10Month13On the afternoon of [Date], the signing ceremony for the Shanghai State-owned Investment Biopharmaceutical Industry Ecosystem Cooperation Fund was held.Pudong Zhongsheng, Cathay-Sanofi Fund,Taifu Capital, Proxima Ventures, Qianji Capital, etc.10On-site signing with the agency.

It is reported that, to support the innovative development of the entire biopharmaceutical industry chain,2024Year,Total Scale225100 million yuanShanghai's Biopharmaceutical Industry Fund of Funds Was Established, Aiming to Build "Patient Capital"+The “Full-Cycle Empowerment” model better leverages the functions of “investing early, investing in small enterprises, making long-term investments, and investing in hard-core technologies,” as well as industrial investment, M&A integration, and strengthening and supplementing supply chains.

2025Year,Total Scale150100 million yuanThe establishment of the Shanghai Future Industry Fund, positioned as counter-cyclical patient capital, leverages the multiplier effect and guiding role of fiscal funds, anchoring on the “nuclear explosion points” of scientific and technological innovation, and focusing on promoting technology “from0To1“Translation of Original Innovations.”

As of2025Year10Shanghai Biopharmaceutical Industry Fund of Funds, Shanghai Future Industry FundCumulative investment decisions in the biomedical sub-fund have approached60100 million yuan, through market-based selection18Sub-fund, with a leverage ratio of nearly6times; the Shanghai Biopharmaceutical Industry Fund of Funds, as a cornerstone investor, has committed capital to the Shanghai Biopharmaceutical M&A Fund22.5100 million yuan.

Just two days before Shanghai State-owned Capital Investment Co., Ltd. signed the agreement,11Month11Recently, the General Office of the Shanghai Municipal People’s Government issued the “Several Measures on Accelerating the Promotion of Frontier Technological Innovation and the Cultivation of Future Industries,” explicitly proposing to expand and strengthen sectors such as cell and gene therapy, biomanufacturing, and embodied intelligence.

and emphasizes support for the establishment of specialized service platforms, including proof-of-concept platforms, pilot-scale testing platforms, and common technology R&D platforms.Provide the maximum as stipulated3000¥10,000 Support; and increase policy support for the first set, first batch, and first edition of future industries, providing support for innovative products that meet the criteria according to regulations.Not exceeding the contract amount30%, Maximum200010,000 Yuan Support。

Meanwhile, Beijing is also increasing its investment in the biotechnology and healthcare sectors.

Recently, Beijing Shali Biopharmaceutical Co., Ltd. completedCRound of financing, with the amount exceeding6hundred million yuan, with participating investors includingShunxi Fund, Yizhuang Holdingsetc.; Lingchuang Medical Valley announces the completion of nearly2100 million yuanBround of financing, led byShunxi Fund,Yizhuang State-owned Capital InvestmentCo-lead investment.

It is understood that Yizhuang Holdings is1992A municipal state-owned enterprise established with the approval of the Beijing Municipal Committee of the Communist Party of China and the Beijing Municipal People's Government, with a registered capital of188100 million yuan, total assets720100 million yuan,Asset Management1333100 million yuan。

Yizhuang State-owned Capital Investment is a state-owned capital investment and operation company, with total assets nearing1400hundred million yuan, with over270items, with the total actual paid-in amount of the project approaching1500¥100 million, assets under management90Remaining units,The total scale of the fund exceeds 1 trillion yuan.

Shunxi Fund, which participated in the financing of the aforementioned two companies, is a full-lifecycle investment platform under Beijing State-owned Capital Management and Operation Group, with a primary focus on investing in strategic emerging industries.

Additionally, this year9Month, Beijing — A Provider of Integrated Platform Solutions for the Large-Scale Intelligent Manufacturing of 3D Cell CulturesHuakan BioAnnounced the successful completion of a financing round worth hundreds of millions of RMBB+Round of financing.

This effort has also received strong support from the Beijing Industrial Investment Fund.According to reports, this financing round attracted participation from multiple leading investment institutions, including the Beijing Pharmaceutical and Health Industry Investment Fund, the Beijing New Materials Industry Investment Fund, Gongrong Shunxi Fund, Jingguorui Fund, China Reform Holdings Corporation Fund, Yuanzhi Capital, CMB International Capital, Chongqing Xiangxinli Fund, Guokang Fund, and Zhongguancun Capital.

It is understood that,2025Year4In May, the Beijing Municipal Healthcare Security Administration and eight other departments issued the “Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Pharmaceuticals (2025Year)》, proposing the construction of500Healthcare Industry Fund with a Scale of Hundreds of Millions of Yuan, newly established100a pharmaceutical M&A fund with a scale of hundreds of millions of yuan, and give full play to the municipal-level200100 million yuan, district-level100Synergy of the Two-Tier Biopharmaceutical Investment Fund Worth Hundreds of Millions of Yuan.

Differences between Beijing and Shanghai, RecentGuangdong’s support for the biomanufacturing industry is primarily policy-oriented.

According to the official website of the People's Government of Guangdong Province, the "Several Measures for Promoting Biomanufacturing to Empower Manufacturing in Guangdong Province" will be issued and implemented in the near future.

《Several Measures》Focusing on prominent issues in the process of empowering manufacturing with biomanufacturing, such as incomplete industrial chains, lagging development of standard systems, and unsound industrial ecosystems, this document proposes specific measures and provides strong support in areas including achievement transformation, promotion and application, dissemination and implementation of standards, and international alignment and mutual recognition of standards.

It is understood that the “Action Plan for Accelerating the Construction of an Innovation Highland for the Biomanufacturing Industry,” issued by Guangdong Province at the beginning of this year, has explicitly stated that the total output value of the province’s biomanufacturing industry will reach2027Year reached5000approximately RMB 100 million, to2035The annual scale is approaching the trillion-yuan level.

Guangzhou and Shenzhen are key cities for achieving output value targets.

Shenzhen is driving the innovative development of the synthetic biology industry through legislation., according to the latest issue of the Municipal Government Gazette, the "Several Provisions of the Shenzhen Special Economic Zone on Promoting the Innovative Development of the Synthetic Biology Industry" have been adopted by the meeting of the Standing Committee of the Shenzhen Municipal People's Congress and officially came into effect recently.

"The Regulations" aim to promote technological innovation and industrial application of synthetic biology, establish a source of synthetic biology innovation and an industrial cluster hub, and drive the high-quality development of the synthetic biology industry.From multiple fields closely related to citizens' lives, including food, pharmaceuticals, and green materials, bringing tangible benefits to Shenzhen residents.

It was also reported that,Guangzhou will also introduce policies related to biomanufacturing,Relevant officials in Guangzhou stated that the new policy will provide robust support for R&D talent in biomanufacturing, as well as for the approval and application of new products. Through a series of measures spanning from source innovation within enterprises to small-scale and pilot-scale trials, product approval, and finally market commercialization, the policy aims to significantly reduce corporate costs.

It is understood that Guangzhou has clearly included the biomanufacturing industry in the “12218“Key development of a modernized industrial system; the city has established a special task force for the development of the biomanufacturing industry, clearly proposing that by”2027By [year], a biomanufacturing industrial cluster with nationwide competitiveness will be initially established.

Currently, Guangzhou hasRiboBio, Moon Biotech and other core technology enterprises spanning the upstream, midstream, and downstream segments of the biomanufacturing industry. In terms of industrial research, it boasts a number of robust scientific research institutions, such as the Center for Basic Sciences in Evolutionary and Synthetic Biology at Sun Yat-sen University and the Research Center for Synthetic Biology at South China University of Technology, providing a solid foundation for industrial development.